Wednesday, June 18, 2025 at 2-3pm ET                            Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Join us for a webinar on the Managed Care Approaches to Bispecific Antibodies, focusing on follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Approximately 81,000 individuals Join us for a webinar on Managed Care Approaches to Bispecific Antibodies, with a focus on follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Each year, approximately 81,000 individuals are diagnosed with non-Hodgkin lymphoma (NHL), resulting in around 20,000 deaths. Follicular lymphoma is the most common subtype of indolent NHL, with a median age of diagnosis at 65 years. FL can transform into diffuse large B-cell lymphoma. DLBCL accounts for about 30% of all annual NHL diagnoses.

This session will feature clinical managed care participants from the roundtable convened by AMCP in April 2025. Presenters will examine the cost-effectiveness of BsAbs compared to alternative treatment pathways for FL and DLBCL, explore payer perspectives on the role of BsAbs, review clinical trial results and real-world evidence for BsAbs, gain insights into best practices for MCOs in managing BsAbs effectively, and provide an update on the unique science, mechanisms of action and dosing protocols of BsAbs.

Learning Objectives

• Provide an update on the unique science, mechanisms of action, and dosing protocols of bispecific antibodies (BsAbs), emphasizing distinctions from traditional monoclonal antibodies and BiTEs, and their role in treatment sequencing for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).
• Review clinical trial results and real-world evidence for BsAbs, focusing on outcomes such as mortality, adverse events, and hospitalizations.
• Examine the cost-effectiveness of BsAbs compared to alternative treatment pathways for FL and DLBCL.
• Explore payer perspectives on the role of BsAbs, including their use in combination therapy, site-of-care considerations, and implications for benefit designs.
• Gain insights into best practices for managed care organizations (MC)s) in managing BsAbs effectively.